CHENGDU, China, 10. Februar 2025 /PRNewswire/ — Keymed Biosciences (HKEX: 02162) gab heute bekannt, dass die National Medical Products Administration (die „NMPA”) von China vor kurzem den ergänzenden Antrag für ein neues Arzneimittel (die „sNDA”) von Stapokibart (monoklonaler Antikörper…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.